-
-
-
-
-
-
-
Johnson & Johnson beats estimates, raises 2026 guidance
-
-
-
-
-
-
-
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
-
-
-
-
-
-
-
HSBC lists 11 potential U.S. outperformers heading into earnings
-
-
-
-
-
-
-
Johnson & Johnson receives FDA approval for CAPLYTA to treat depression
-
-
-
-
-
-
-
Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook
-
-
-
-
-
-
-
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
-
-
-
-
-
-
-
Johnson & Johnson earnings preview Q2: flat print expected, tariff impact in focus
-
1,198,854 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

